BioCentury | May 21, 2012
Company News

Neurotune, ALS Therapy Development Institute (ALS TDI) deal

...ALS TDI said it will evaluate the efficacy of Neurotune's TDI-165 in a preclinical model of...
...ALS). TDI-165 is a biologic targeted at stabilizing the neuromuscular junction. Details were not disclosed. Neurotune AG...
BioCentury | Mar 26, 2012
Company News

Neurotune sales and marketing update

...Eureka-Eurostars programme, a European program that provides R&D funding for small and medium-sized enterprises (SMEs). Neurotune AG...
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Musculoskeletal disease

...cancer-associated muscle loss. GlaxoSmithKline plc's GSK2245840 (SRT2104) is in Phase I testing for muscle atrophy. Neurotune AG...
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...cancer-associated muscle loss. GlaxoSmithKline plc's GSK2245840 (SRT2104) is in Phase I testing for muscle atrophy. Neurotune AG...
BioCentury | Apr 18, 2011
Company News

Neurotune management update

Neurotune AG , Schlieren, Switzerland Business: Neurology, Musculoskeletal Transitioned: Armin Mader to CEO from CFO; he replaces Executive Chairman Bruno Oesch, who will now focus on strategic and business development WIR Staff Musculoskeletal Neurology...
BioCentury | Nov 8, 2010
Clinical News

Dimiracetam: Phase IIa data

...vs. 25%, p=0.47), or with worsening of their general clinical condition (2.9% vs. 2.1%, p=1.0). Neurotune...
...800 mg dimiracetam for 2 weeks, and then twice-daily 1,600 mg dimiracetam for 4 weeks. Neurotune AG...
BioCentury | Aug 23, 2010
Regulation

Run off the road

...Pharmaceuticals Holdings Inc. (NASDAQ:ENDP)/Gruenenthal Group Axomadol Analgesic Ph II [moderate-to-severe chronic pain; diabetic peripheral neuropathy] Neurotune AG...
BioCentury | Dec 3, 2009
Targets & Mechanisms

Good touch, bad touch

...VGLUT3 could potentially synergize with direct inhibition of glutamate receptors. However, Bruno Oesch, CEO of Neurotune AG...
...have glutamate-modulating compounds in development for various pain indications. The majority antagonize NMDA-type glutamate receptors. Neurotune's...
...Osherovich, L. SciBX 2 (46); doi:10.1038/scibx.2009.1685 Published online Dec. 3, 2009 Companies and Institutions Mentioned Neurotune AG...
BioCentury | Apr 2, 2009
Cover Story

New PrPetrator in AD

...the company has spun out most of its human therapeutics program into a new company, Neurotune AG...
...2, 2009 Companies and Institutions Mentioned Gladstone Institute of Neurological Disease , San Francisco, Calif. Neurotune AG...
BioCentury | Jan 26, 2009
Clinical News

Dimiracetam: Phase I data

...of food interaction followed by a double-blind, placebo-controlled portion of twice-daily dosing for 14 days. Neurotune AG...
Items per page:
1 - 10 of 16
BioCentury | May 21, 2012
Company News

Neurotune, ALS Therapy Development Institute (ALS TDI) deal

...ALS TDI said it will evaluate the efficacy of Neurotune's TDI-165 in a preclinical model of...
...ALS). TDI-165 is a biologic targeted at stabilizing the neuromuscular junction. Details were not disclosed. Neurotune AG...
BioCentury | Mar 26, 2012
Company News

Neurotune sales and marketing update

...Eureka-Eurostars programme, a European program that provides R&D funding for small and medium-sized enterprises (SMEs). Neurotune AG...
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Musculoskeletal disease

...cancer-associated muscle loss. GlaxoSmithKline plc's GSK2245840 (SRT2104) is in Phase I testing for muscle atrophy. Neurotune AG...
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...cancer-associated muscle loss. GlaxoSmithKline plc's GSK2245840 (SRT2104) is in Phase I testing for muscle atrophy. Neurotune AG...
BioCentury | Apr 18, 2011
Company News

Neurotune management update

Neurotune AG , Schlieren, Switzerland Business: Neurology, Musculoskeletal Transitioned: Armin Mader to CEO from CFO; he replaces Executive Chairman Bruno Oesch, who will now focus on strategic and business development WIR Staff Musculoskeletal Neurology...
BioCentury | Nov 8, 2010
Clinical News

Dimiracetam: Phase IIa data

...vs. 25%, p=0.47), or with worsening of their general clinical condition (2.9% vs. 2.1%, p=1.0). Neurotune...
...800 mg dimiracetam for 2 weeks, and then twice-daily 1,600 mg dimiracetam for 4 weeks. Neurotune AG...
BioCentury | Aug 23, 2010
Regulation

Run off the road

...Pharmaceuticals Holdings Inc. (NASDAQ:ENDP)/Gruenenthal Group Axomadol Analgesic Ph II [moderate-to-severe chronic pain; diabetic peripheral neuropathy] Neurotune AG...
BioCentury | Dec 3, 2009
Targets & Mechanisms

Good touch, bad touch

...VGLUT3 could potentially synergize with direct inhibition of glutamate receptors. However, Bruno Oesch, CEO of Neurotune AG...
...have glutamate-modulating compounds in development for various pain indications. The majority antagonize NMDA-type glutamate receptors. Neurotune's...
...Osherovich, L. SciBX 2 (46); doi:10.1038/scibx.2009.1685 Published online Dec. 3, 2009 Companies and Institutions Mentioned Neurotune AG...
BioCentury | Apr 2, 2009
Cover Story

New PrPetrator in AD

...the company has spun out most of its human therapeutics program into a new company, Neurotune AG...
...2, 2009 Companies and Institutions Mentioned Gladstone Institute of Neurological Disease , San Francisco, Calif. Neurotune AG...
BioCentury | Jan 26, 2009
Clinical News

Dimiracetam: Phase I data

...of food interaction followed by a double-blind, placebo-controlled portion of twice-daily dosing for 14 days. Neurotune AG...
Items per page:
1 - 10 of 16